I express my deepest gratitude to the @myESMO community, my esteemed colleagues, and friends for trusting me to serve as the next president of the Society.
We are committed to dedicating all our efforts to advancing oncology and improving the lives of our patients.
Thrilled to welcome #ESMO2024 after a challenging year! A heartfelt thank you to the global medical oncology community for your unwavering support. Together, we’ll continue to advance the field and serve our global society with dedication and innovation @myESMO@oncodaily
See our article 👉Targeting pan-cancer RET fusions featured in the cover of @NatureMedicine. Many years of work, a stellar team and many patients who generously believed in the science of precision medicine. @IEOufficiale@LaStatale
Excited to share that the DESTINY-06 trial was presented at #ASCO2024 and received fantastic feedback from our outstanding audience! A huge thank you to everyone who attended and supported our work in advancing cancer treatment. Together, we’re making strides in oncology!
Thrilled to announce the publication of the final overall survival data of DESTINY-03 in Nature Medicine, coinciding with its presentation at #ASCO2024! This marks a significant milestone in our fight against cancer. Thank you to everyone involved for your dedication and support!
Don't just teach your students to read.
• Teach them to question what they read, what they study.
• Teach them to doubt.
• Teach them to think.
• Teach them to make mistakes and learn from them.
• Teach them how to understand something.
• Teach them how to teach others
We just lost another giant of cancer care. Our friend Angelo Di Leo is no more with us. I will profoundly miss him! @myESMO @BIGagainstBC @AIOMtweet@ASCO
Investing in the next generation of oncologists is crucial for the future of cancer research. At #ASCO2024, let's continue to support and mentor young talents who will drive innovation and breakthroughs in oncology. Together, we can achieve more! #YoungOncologists#CancerResearch
Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 - Annals of Oncology
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies | npj Breast Cancer nature.com/articles/s4152…
The #ASCO meeting is about to begin, featuring breakthrough data on cancer treatment across various pathologies. Stay tuned for groundbreaking updates that could change the future of oncology! #CancerResearch#MedicalInnovation#ASCO2024
